Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$97.73 USD

97.73
1,180,791

+0.46 (0.47%)

Updated May 6, 2024 04:00 PM ET

After-Market: $97.83 +0.10 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition

by Zacks Equity Research

Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.

The Zacks Analyst Blog Highlights Novartis, Amgen, Palo Alto, Brown & Brown and Ericsson

by Zacks Equity Research

Novartis, Amgen, Palo Alto, Brown & Brown and Ericsson are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Novartis, Amgen & Palo Alto Networks

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW).

Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.

Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.

Pfizer (PFE) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.

Ekta Bagri headshot

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

by Ekta Bagri

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

Novartis (NVS) Stock Moves 0.22%: What You Should Know

by Zacks Equity Research

In the most recent trading session, Novartis (NVS) closed at $108.47, indicating a +0.22% shift from the previous trading day.

J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

Novartis (NVS) closed at $108.03 in the latest trading session, marking a -0.21% move from the prior day.

Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024

by Zacks Equity Research

Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.

Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Annexon, Inc. (ANNX) and Novartis (NVS) have performed compared to their sector so far this year.

Zacks Investment Ideas feature highlights: Eli Lilly and Novartis

by Zacks Equity Research

Eli Lilly and Novartis have been highlighted in this Investment Ideas article.

Bryan Hayes headshot

These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High

by Bryan Hayes

As investors, our job isn't to predict an unknowable future.

Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

The latest trading day saw Novartis (NVS) settling at $107.45, representing a -0.14% change from its previous close.

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

by Zacks Equity Research

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

Novartis (NVS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Novartis (NVS) closed at $107.60, marking a +0.15% move from the previous day.

Andrew Rocco headshot

Bullish Continuation in '24? 3 Market Areas to Watch

by Andrew Rocco

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis

by Zacks Equity Research

Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.

Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates

by Zacks Equity Research

Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.

The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group

by Zacks Equity Research

Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.

Novartis (NVS) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

In the most recent trading session, Novartis (NVS) closed at $106.31, indicating a +0.7% shift from the previous trading day.

Mark Vickery headshot

Top Analyst Reports for Merck, Salesforce & Philip Morris

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).

NVS or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?